Article
Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and Imatinib-treated chronic myeloid leukemia patients.
Leukemia research - 1 May 2014
Estrada-González P K, Gómez-Ceja L, Montesinos J J, Mayani H, Chávez-González A, Meillón L, Delgado N, Sánchez-Nava E, Flores-Figueroa E
Abstract excerpt
In vitro, Imatinib inhibits the proliferation and stimulates the osteogenic and adipogenic differentiation of mesenchymal stromal cells (MSC). However, it is unknown whether Imatinib affects the biology of MSC in vivo. We asked whether MSC from long-term Imatinib-treated CML patients were affected by the in vivo treatment. MSC from untreated and Imatinib-treated patients displayed normal functional properties...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.